| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets AJ Souers, JD Leverson, ER Boghaert, SL Ackler, ND Catron, J Chen, ... Nature medicine 19 (2), 202-208, 2013 | 3118 | 2013 |
| The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase CAP Joazeiro, SS Wing, H Huang, JD Leverson, T Hunter, YC Liu Science 286 (5438), 309-312, 1999 | 1300 | 1999 |
| Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia M Konopleva, DA Pollyea, J Potluri, B Chyla, L Hogdal, T Busman, ... Cancer discovery 6 (10), 1106-1117, 2016 | 1034 | 2016 |
| From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors A Ashkenazi, WJ Fairbrother, JD Leverson, AJ Souers Nature reviews drug discovery 16 (4), 273-284, 2017 | 867 | 2017 |
| Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia R Pan, LJ Hogdal, JM Benito, D Bucci, L Han, G Borthakur, J Cortes, ... Cancer discovery 4 (3), 362-375, 2014 | 728 | 2014 |
| Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy JD Leverson, DC Phillips, MJ Mitten, ER Boghaert, D Diaz, SK Tahir, ... Science translational medicine 7 (279), 279ra40-279ra40, 2015 | 550 | 2015 |
| Efficacy of venetoclax as targeted therapy for relapsed/refractory t (11; 14) multiple myeloma S Kumar, JL Kaufman, C Gasparetto, J Mikhael, R Vij, B Pegourie, ... Blood, The Journal of the American Society of Hematology 130 (22), 2401-2409, 2017 | 528 | 2017 |
| Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference C Zhu, J Zhao, M Bibikova, JD Leverson, E Bossy-Wetzel, JB Fan, ... Molecular biology of the cell 16 (7), 3187-3199, 2005 | 517 | 2005 |
| The Inhibitor of Apoptosis, cIAP2, Functions as a Ubiquitin-Protein Ligase and Promotes in VitroMonoubiquitination of Caspases 3 and 7 H Huang, CAP Joazeiro, E Bonfoco, S Kamada, JD Leverson, T Hunter Journal of Biological Chemistry 275 (35), 26661-26664, 2000 | 509 | 2000 |
| Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) JD Leverson, H Zhang, J Chen, SK Tahir, DC Phillips, J Xue, P Nimmer, ... Cell death & disease 6 (1), e1590-e1590, 2015 | 495 | 2015 |
| Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins H Sun, JD Leverson, T Hunter The EMBO journal 26 (18), 4102-4112, 2007 | 365 | 2007 |
| Pim-1 kinase and p100 cooperate to enhance c-Myb activity JD Leverson, PJ Koskinen, FC Orrico, EM Rainio, KJ Jalkanen, AB Dash, ... Molecular cell 2 (4), 417-425, 1998 | 345 | 1998 |
| Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity ZF Tao, L Hasvold, L Wang, X Wang, AM Petros, CH Park, ER Boghaert, ... ACS medicinal chemistry letters 5 (10), 1088-1093, 2014 | 315 | 2014 |
| The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t (11; 14) multiple myeloma C Touzeau, C Dousset, S Le Gouill, D Sampath, JD Leverson, AJ Souers, ... Leukemia 28 (1), 210-212, 2014 | 300 | 2014 |
| Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models EA Punnoose, JD Leverson, F Peale, ER Boghaert, LD Belmont, N Tan, ... Molecular cancer therapeutics 15 (5), 1132-1144, 2016 | 298 | 2016 |
| Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM P Moreau, A Chanan-Khan, AW Roberts, AB Agarwal, T Facon, S Kumar, ... Blood, The Journal of the American Society of Hematology 130 (22), 2392-2400, 2017 | 291 | 2017 |
| Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo Y Luo, AR Shoemaker, X Liu, KW Woods, SA Thomas, R de Jong, EK Han, ... Molecular cancer therapeutics 4 (6), 977-986, 2005 | 275 | 2005 |
| Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy R Pan, V Ruvolo, H Mu, JD Leverson, G Nichols, JC Reed, M Konopleva, ... Cancer cell 32 (6), 748-760. e6, 2017 | 254 | 2017 |
| The APC11 RING-H2 finger mediates E2-dependent ubiquitination JD Leverson, CAP Joazeiro, AM Page, H Huang, P Hieter, T Hunter Molecular biology of the cell 11 (7), 2315-2325, 2000 | 229 | 2000 |
| Potential mechanisms of resistance to venetoclax and strategies to circumvent it SK Tahir, ML Smith, P Hessler, LR Rapp, KB Idler, CH Park, JD Leverson, ... BMC cancer 17, 1-10, 2017 | 212 | 2017 |
